AstraZeneca is beginning to see momentum behind its oncology portfolio. CFO Aradhana Sarin says the work is only just beginning.
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.